PATENT CLAIM ANALYSIS

Application Number: 16214214
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["514", "04400R"]

Abstract:
The present invention relates to compositions and methods for the delivery of therapeutic proteins to the CNS using recombinant AAV vectors. More specifically, the invention relates to compositions and methods for delivering proteins into the cerebrospinal fluid of mammalian subjects through peripheral administration of AAV vectors. The invention may be used to treat various disorders of the central nervous system, including degenerative diseases and motor neuron diseases.

Claim (Index 17):
The method according to  claim 14 , wherein the AAV vector has a replication defective AAV genome lacking functional Rep and Cap encoding viral sequences.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 98.0
- Lexical Diversity: 1.56522
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12452789', '12734016', '13388083', '14445670', '11934325']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7892894021789588
- 35 USC 102 Novelty (BERT): 0.6709814901211638
- Combined Prediction Score: 0.7774586109731794
- Mean Citation Score: 468.141834
- Max Citation Score: 728.23615
- Similarity Product: 630.6227267769248

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test